As presented at #ESMO2026, perioperative #durvalumab plus neoadjuvant enfortumab vedotin significantly improved survival in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based therapy.

Learn more: https://www.hmpgloballearningnetwork.com/site/onc/news/volga-trial-demonstrates-significant-survival-benefit-durvalumab-plus-enfortumab